Travel Medicine and Infectious Disease最新文献

{"title":"The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective.","authors":"Francesca Rovida, Marino Faccini, Carla Molina Granè, Irene Cassaniti, Sabrina Senatore, Eva Rossetti, Giuditta Scardina, Manuela Piazza, Giulia Campanini, Daniele Lilleri, Stefania Paolucci, Guglielmo Ferrari, Antonio Piralla, Francesco Defilippo, Davide Lelli, Ana Moreno, Luigi Vezzosi, Federica Attanasi, Marzia Soresini, Manuela Barozzi, Lorenzo Cerutti, Stefano Paglia, Angelo Regazzetti, Maurilia Marcacci, Guido Di Donato, Marco Farioli, Mattia Manica, Piero Poletti, Antonio Lavazza, Maira Bonini, Stefano Merler, Fausto Baldanti, Danilo Cereda","doi":"10.1016/j.tmaid.2025.102795","DOIUrl":"10.1016/j.tmaid.2025.102795","url":null,"abstract":"<p><strong>Introduction: </strong>Here we reported the virological, entomological and epidemiological characteristics of the large autochthonous outbreak of dengue (DENV) occurred in a small village of the Lombardy region (Northern Italy) during summer 2023.</p><p><strong>Methods: </strong>After the diagnosis of the first autochthonous case on August 18, 2023, public health measures, including epidemiological investigation and vector control measures, were carried out. A serological screening for DENV antibodies detection was offered to the population. In the case of positive DENV IgM, a second sample was collected to detect DENV RNA and verify seroconversion. Entomological and epidemiological investigations were also performed. A modeling analysis was conducted to estimate the dengue generation time, transmission potential, distance of transmission, and assess diagnostic delays.</p><p><strong>Results: </strong>Overall, 416 subjects participated to the screening program and 20 were identified as DENV-1 cases (15 confirmed and 5 probable). In addition, DENV-1 infection was diagnosed in 24 symptomatic subjects referred to the local Emergency Room Department for suggestive symptoms and 1 case was identified through blood donation screening. The average generation time was estimated to be 18.3 days (95 % CI: 13.1-23.5 days). R₀ was estimated at 1.31 (95 % CI: 0.76-1.98); 90 % of transmission occurred within 500m. Entomological investigations performed in 46 pools of mosquitoes revealed the presence of only one positive pool for DENV-1.</p><p><strong>Discussion: </strong>This report highlights the importance of synergic surveillance, including virological, entomological and public health measures to control the spread of arboviral infections.</p>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":" ","pages":"102795"},"PeriodicalIF":6.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icterus provoked by Echinococcus mimicking a tumor: A diagnostic challenge.","authors":"Bojan Miletic, Yves Sutter, Elefteri Buset, Silvije Segulja, Marcus Hesse","doi":"10.1016/j.tmaid.2024.102790","DOIUrl":"10.1016/j.tmaid.2024.102790","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"102790"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study.","authors":"Yin Yin, Min Jia, Yufeng Li, Wei Zhao, Shuhong Chen, Peiyuan Huo, Qinghua Zhao, Lan Yu, Cha Wang, Yirui Ma, Meixia Wang, Jing Zhang","doi":"10.1016/j.tmaid.2024.102792","DOIUrl":"10.1016/j.tmaid.2024.102792","url":null,"abstract":"<p><strong>Background: </strong>The combination of passive immune agents (human rabies immune globulin (HRIG) and equine rabies antiserum (ERA)) with vaccines are effective measures for preventing the onset of rabies post exposure. However, ERA and HRIG have potential risks of serum allergic reactions and blood-transmitted infectious diseases. This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone.</p><p><strong>Method: </strong>This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals.</p><p><strong>Results: </strong>The rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines showed favorable safety and presented the pharmacokinetic property of linear elimination. The antibody neutralizing activity of rhRIG has the same level as HRIG in combination with vaccines. The rhRIG did not affect the long-term protective effect of the vaccine.</p><p><strong>Conclusions: </strong>The rhRIG could provide immediate immune protection at the wound site and producing earlier protection during the window period before the rabies vaccine established active immunity. Therefore, it is recommended to continue to evaluate the safety and antibody neutralizing activity of rhRIG (20 and 40IU/kg) in combination with the vaccine in Phase II clinical trials.</p><p><strong>Trials registration: </strong>ChiCTR1900023785 (https://www.chictr.org.cn).</p>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":" ","pages":"102792"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Demographic, epidemiological and clinical characteristics of Ukrainian war refugees with HIV infection in the Slovak Republic\" [Travel Med Infect Dis 62 (2024) 102764].","authors":"Ricardo Massmann, Kristína Doležalová Mgr, Lubomír Soják, Olena Samsonová, Danica Valkovičová Staneková, Ondrej Zahornacký, Pavol Jarčuška, Mária Záriš Vachalíková, Diana Vološinová, Ľubica Piesecká, Veronika Vahalová, Katarína Šimeková, Terézia Smiešková, Alexandra Bražinová, Ivy Kigen, Marek Malý, Ladislav Machala","doi":"10.1016/j.tmaid.2024.102791","DOIUrl":"10.1016/j.tmaid.2024.102791","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"102791"},"PeriodicalIF":6.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials.","authors":"Xiao Liu, Jiayu Zhang, Fuwei Liu, Yifan Wu, Lin Li, Ruoyun Fan, Changchang Fang, Jinyi Huang, Deju Zhang, Peng Yu, Huilei Zhao","doi":"10.1016/j.tmaid.2024.102793","DOIUrl":"10.1016/j.tmaid.2024.102793","url":null,"abstract":"<p><strong>Background: </strong>There is substantial epidemiological evidence demonstrating that influenza contributes to cardiovascular events in patients who already have cardiovascular diseases. However, the efficacy of influenza vaccination on the prognosis of patients with ischemic heart disease (IHD) is unclear.</p><p><strong>Methods: </strong>We conducted a systematic search for eligible randomized controlled trials (RCTs) in PubMed, Cochrane, and Embase on September 13, 2024, to investigate the effects of the influenza vaccine on the prognosis of patients with IHD. The effect sizes were combined using random-effects models, and Trial Sequential Analysis (TSA) was used to assess the reliability and validity of the results.</p><p><strong>Results: </strong>Five RCTs with a total of 5659 patients (median age ranging from 57.1 to 66 years, 67.8% male) with IHD were included. The use of influenza vaccine reduced the risk of major adverse cardiovascular events (risk ratio [RR] = 0.67, 95% confidence interval [CI] 0.52-0.87, number-needed-to-treat [NNT] of 37, high certainty), cardiovascular death (RR = 0.55, 95% CI 0.35-0.87, moderate certainty), all-cause mortality (RR = 0.58, 95% CI 0.40-0.84, high certainty) and myocardial infarction (MI) (RR = 0.66, 95% CI 0.46-0.93, high certainty) in patients with IHD compared with control. The analysis revealed no significant benefit regarding hospitalization for heart failure (HF) (RR = 0.91, 95% CI 0.21-3.99, moderate certainty) and revascularization (RR = 0.59, 95% CI 0.10-3.45, moderate certainty). The NNT to avoid 1 event was 37 for major adverse cardiovascular events, 56 for cardiovascular death, 67 for MI, and 41 for all-cause death. TSA showed that the benefit of influenza vaccine in reducing MACE was conclusive, no more trials were necessary.</p><p><strong>Conclusion: </strong>This study suggests high level of evidence that the use of influenza vaccine may reduce the risk of major adverse cardiovascular events in patients with IHD.</p>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":" ","pages":"102793"},"PeriodicalIF":6.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"Gerard T. Flaherty","doi":"10.1016/j.tmaid.2024.102788","DOIUrl":"10.1016/j.tmaid.2024.102788","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102788"},"PeriodicalIF":6.3,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular infections in international travelers","authors":"Francesca F. Norman ,&nbsp;Julio J. González-López ,&nbsp;Diego Gayoso-Cantero ,&nbsp;Marta Vicente-Antolin ,&nbsp;Maria-Dolores Corbacho-Loarte ,&nbsp;Rogelio López-Vélez ,&nbsp;Marta González-Sanz","doi":"10.1016/j.tmaid.2024.102789","DOIUrl":"10.1016/j.tmaid.2024.102789","url":null,"abstract":"<div><h3>Introduction</h3><div>Ophthalmological conditions in international travelers may be associated with low mortality but high morbidity. Eye involvement in travelers is less frequently reported than febrile, gastrointestinal and respiratory infections, but data probably represent a degree of under-notification.</div></div><div><h3>Methods</h3><div>an extensive narrative review of the main viral, bacterial, fungal and parasitic infections affecting the eye in travelers was performed.</div></div><div><h3>Main findings</h3><div>Common respiratory tract viral infections may cause ocular complications in travelers, human influenza viruses have been associated with conjunctivitis and emerging avian influenza subtypes may also affect the eye. Vector-borne viral infections may affect travelers, usually with systemic symptoms, but eye disease may be the first presenting feature. A spectrum of manifestations have been described with dengue, chikungunya and Zika infections, including conjunctivitis, anterior uveitis, posterior uveitis with chorioretinitis and macular involvement. <em>Staphylococcus</em> spp, <em>Streptococcus</em> spp, and <em>Pseudomonas</em> spp (especially associated with use of contact lenses) are common causes of keratitis, however, resistance patterns to antimicrobials might vary depending on area of travel. Less frequent infections, such as <em>Burkholderia pseudomallei</em>, associated with environmental exposure, and <em>Bartonella</em> spp. may rarely present with ophthalmological involvement in travelers. Fungal ocular infections, especially after ocular trauma caused by plants and contact lens use, should be considered in patients with stromal keratitis not improving with antibiotic eye drops. Parasitic eye infections tend to occur in tropical areas, but some, such as acanthamoebic keratitis or <em>Toxoplasma</em> spp retinitis, are found worldwide. Increasing exposure to animals, undercooked food consumption or poor hygiene during international travels might be leading to the emergence of certain parasitic eye diseases.</div></div><div><h3>Conclusions</h3><div>Clinical features, with identification of risk factors and geographical region of exposure, can assist in the definitive diagnosis of imported ophthalmological infections. Management of imported eye infections requires a multi-disciplinary approach involving ophthalmologists, travel medicine/infectious diseases physicians and other specialists.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102789"},"PeriodicalIF":6.3,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccinations for Hajj: Enhancing health and global health security","authors":"Anas A. Khan ,&nbsp;Bander S. Balkhi ,&nbsp;Fahad A. Alamri ,&nbsp;Ghadah S. Alsaleh ,&nbsp;Jaffar A. Al-Tawfiq ,&nbsp;Hani Jokhdar","doi":"10.1016/j.tmaid.2024.102784","DOIUrl":"10.1016/j.tmaid.2024.102784","url":null,"abstract":"<div><div>The Hajj pilgrimage, one of the world's largest and most diverse mass gatherings, poses unique challenges for preventing infectious disease outbreaks. Vaccinations are vital in reducing the risk and spread of diseases during this event. This narrative review examines the impact of vaccination programs on infectious disease mitigation during the Hajj and their broader implications for global health security (GHS). Mandatory vaccination protocols against Meningococcal Meningitis, Yellow Fever, Influenza, pneumococcal diseases, and COVID-19 have demonstrated significant success in controlling infection spread during Hajj. Furthermore, the integration of digital health passports or similar technologies offers the potential to enhance surveillance, streamline vaccination verification, and further minimize risks associated with mass gatherings. This study demonstrates the critical role of vaccination programs in protecting pilgrims. It also explores how technologies can be used to monitor pilgrim health status, enabling rapid identification and mitigation of potential outbreaks, thus contributing to GHS.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102784"},"PeriodicalIF":6.3,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and response to the COVID-19 pandemic in the Dadaab Refugee Camp Complex, Kenya, March 2020–December 2022","authors":"Maurice Ope ,&nbsp;Raymond Musyoka ,&nbsp;Abdihakim Kosar ,&nbsp;Mohammed Osman ,&nbsp;Abdijamal Hassan ,&nbsp;Hussein Mohammed ,&nbsp;Penina Munyua ,&nbsp;Bonventure Juma ,&nbsp;Elizabeth Hunsperger ,&nbsp;Sofia Mohammed ,&nbsp;John Burton ,&nbsp;Rachel B. Eidex","doi":"10.1016/j.tmaid.2024.102785","DOIUrl":"10.1016/j.tmaid.2024.102785","url":null,"abstract":"<div><h3>Introduction</h3><div>Refugee settings may increase the risk of SARS-CoV-2 infection and death, yet data on the response to the pandemic in these populations is scarce.</div></div><div><h3>Methods</h3><div>We describe interventions to mitigate SARS-CoV-2 transmission in Dadaab Refugee Camp Complex, Kenya and performed descriptive analyses using March 2020 to December 2022 data from Kenya's national SARS-CoV-2 repository and line list of positive cases maintained by United Nations High Commissioner for Refugees (UNHCR). We calculated case fatality rates (CFR) and attack rates per 100,000 (AR) using the 2019 national census and population statistics from UNHCR and compared them to national figures.</div></div><div><h3>Results</h3><div>SARS-CoV-2 infection was first reported in April and May 2020, among host community members and refugees respectively. Of 964 laboratory-confirmed cases, 700 (72.6 %) were refugees. The AR was 82.7 (95 % CI 72.6–92.8) for host community members, 228.3 (95 % CI 211.3–245.4) for refugees and 721.1 (95 % CI 718.7–723.5) nationally. The CFR was 1.5 % (95 % CI 0.15–3.18) for host community members, 1.76 % (95 % CI 1.71–1.80) nationally and 7.4 % (95 % CI 5.4–9.4) for refugees.</div><div>Mitigation measures implemented by the Government of Kenya, UNHCR and partners during the pandemic included multisectoral coordination, movement restrictions, mass gathering bans, and health promotion. Social distancing, symptom screening and mandatory mask usage were enforced during mass gatherings. Testing capacity was bolstered, quarantine and isolation facilities established, and vaccination initiated.</div></div><div><h3>Conclusions</h3><div>Despite a low AR and UNHCR's swift and comprehensive response, refugees' CFR was high, underscoring their vulnerability and need for targeted interventions during epidemic responses.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102785"},"PeriodicalIF":6.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking scabies in Europe: An ECDC prevention framework approach","authors":"Giancarlo Ceccarelli,&nbsp;Francesco Branda,&nbsp;Fabio Scarpa,&nbsp;Mattia Albanese,&nbsp;Gabriella d’Ettorre,&nbsp;Marta Giovanetti,&nbsp;Massimo Ciccozzi","doi":"10.1016/j.tmaid.2024.102786","DOIUrl":"10.1016/j.tmaid.2024.102786","url":null,"abstract":"","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"63 ","pages":"Article 102786"},"PeriodicalIF":6.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}